The Clinical Core seeks to improve the diagnosis and management of individuals with Parkinson disease (PD) through its support of the JHU Udall Center and Clinical Project 3. With this funding period request, the Clinical Core will add biofluid ascertainment (blood, urine, and cerebrospinal fluid (CSF)) to its existing 15-year longitudinal study and brain autopsy program. Through the collection of biofluids from individuals who undergo autopsy the Clinical Core is uniquely situated to allow the Clinical Project to identify PD biomarkers. In addition, to ensure that the Clinical Project has sufficient CSF to complete its aims, the Clinical Core will be responsible for obtaining CSF through collaborations with other cohorts both within and outside JHU. The Clinical Core also seeks to fulfill the mission of the JHU Udall Center through its efforts to educate patients, their families, and health care providers regarding the Center's research activities, PD diagnosis and treatment.

Public Health Relevance

The Clinical Core will be a shared resource of the Parkinson's Disease Research Center and will play a central role in our investigations in the pathogenesis of Parkinson's Disease. The Clinical Core will provide vital support to the Clinical Project 3 through its acquisition of cerebrospinal fluid. It will also support the missions of the other cores and projects through its longitudinal investigation and brain autopsy program as well as education initiatives.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
2P50NS038377-16
Application #
8882842
Study Section
Special Emphasis Panel (ZNS1-SRB-J (07))
Project Start
Project End
Budget Start
2014-09-30
Budget End
2015-07-31
Support Year
16
Fiscal Year
2014
Total Cost
$275,400
Indirect Cost
$105,400
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Mills, Kelly A; Mari, Zoltan; Bakker, Catherine et al. (2016) Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients. Parkinsonism Relat Disord 33:102-106
Mao, Xiaobo; Ou, Michael Tianhao; Karuppagounder, Senthilkumar S et al. (2016) Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353:
Geiger, Joshua T; Arthur, Karissa C; Dawson, Ted M et al. (2016) C9orf72 Hexanucleotide Repeat Analysis in Cases with Pathologically Confirmed Dementia with Lewy Bodies. Neurodegener Dis 16:370-2
Mata, Ignacio F; Leverenz, James B; Weintraub, Daniel et al. (2016) GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord 31:95-102
Rosenthal, Liana S; Drake, Daniel; Alcalay, Roy N et al. (2016) The NINDS Parkinson's disease biomarkers program. Mov Disord 31:915-23
Jo, Junghyun; Xiao, Yixin; Sun, Alfred Xuyang et al. (2016) Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons. Cell Stem Cell 19:248-57
Karuppagounder, Senthilkumar S; Xiong, Yulan; Lee, Yunjong et al. (2016) LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity. J Chem Neuroanat 76:90-97
Davis, Marie Y; Johnson, Catherine O; Leverenz, James B et al. (2016) Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurol 73:1217-1224
Nucifora Jr, Frederick C; Nucifora, Leslie G; Ng, Chee-Hoe et al. (2016) Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1. Nat Commun 7:11792
Mills, Kelly A; Mari, Zoltan; Pontone, Gregory M et al. (2016) Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes. Parkinsonism Relat Disord 33:107-114

Showing the most recent 10 out of 206 publications